These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 17713351)

  • 1. Dose requirements among hemodialysis patients treated with darbepoetin-alpha or epoetin-beta.
    Prata MM; Dos Santos JP; Hegbrant J; Schmid CH; Pereira BJ; Wald R
    Nephron Clin Pract; 2007; 107(2):c50-5. PubMed ID: 17713351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
    Berger A; Edelsberg J; Kallich J; Oster G
    Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization and cost in clinical practice of darbepoetin alfa and epoetin alfa for anemia concomitant with chemotherapy.
    Berger A; Lord C; Corey-Lisle PK; Williams GR; Oster G
    Clin Ther; 2012 Jun; 34(6):1350-63. PubMed ID: 22591754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.
    Sharma A; Yee J; Gandra SR; Khan I; Petersen J
    Curr Med Res Opin; 2010 Nov; 26(11):2679-87. PubMed ID: 20942616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta.
    Bock HA; Hirt-Minkowski P; Brünisholz M; Keusch G; Rey S; von Albertini B;
    Nephrol Dial Transplant; 2008 Jan; 23(1):301-8. PubMed ID: 17890745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients.
    Courtney AE; McNamee PT; Maxwell AP
    Nephron Clin Pract; 2007; 107(1):c14-9. PubMed ID: 17664890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from epoetin alpha to darbepoetin alpha in Japanese hemodialysis patients: dose conversion ratio.
    Hirai T; Sugiya N; Nakashima A; Takasugi N; Yorioka N
    Nephron Clin Pract; 2009; 111(2):c81-6. PubMed ID: 19088483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Resistance index to epoetin alpha and to darbepoetin-alpha in chronic hemodialysis patients: a cohort study].
    Pérez-García R; Rodríguez Benítez P; Jofre R; López-Gómez JM; Villaverde MT; Blanco A; Blanco S; Sánchez M
    Nefrologia; 2007; 27(3):340-9. PubMed ID: 17725454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
    Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.
    Agrawal V; Mukherjee S; Kosuri R; Dumler F
    Am J Ther; 2010; 17(5):469-75. PubMed ID: 19770634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
    Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
    Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term intravenous epoetin-alpha / darbepoetin-alpha ratio in iron-replete hemodialysis patients.
    Icardi A; Sacco P; Salvatore F; Romano U
    J Nephrol; 2007; 20(1):73-9. PubMed ID: 17347977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study.
    Tolman C; Richardson D; Bartlett C; Will E
    J Am Soc Nephrol; 2005 May; 16(5):1463-70. PubMed ID: 15788469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa.
    Aarup M; Bryndum J; Dieperink H; Joffe P
    Nephrol Dial Transplant; 2006 May; 21(5):1312-6. PubMed ID: 16396971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease.
    Roger SD; Suranyi MG; Walker RG; Disney A; Isbel NM; Kairaitis L; Pollock CA; Brown FG; Chow J; Truman MI; Ulyate KA;
    Curr Med Res Opin; 2008 Aug; 24(8):2181-7. PubMed ID: 18565240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Change of EPO treatment from subcutaneous epoetin to intravenous epoetin or darbepoetin alpha].
    Molina M; García Hernández MA; Navarro MJ; De Gracia MC; Ortuño T
    Nefrologia; 2004; 24(6):564-71. PubMed ID: 15683029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evolution of the darbepoetin alpha resistance index in patients on dialysis who change from weekly to fortnightly treatments in clinical practice].
    López-Gómez JM; de Francisco AL; Montenegro J; de Santiago C; Vera M; Donapetry C; Villaverde M
    Nefrologia; 2010; 30(1):64-72. PubMed ID: 20098471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.